Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan 12;6(1):18.
doi: 10.1038/s41392-020-00459-2.

Identification of MSA-2: An oral antitumor non-nucleotide STING agonist

Jianhua Liu  1   2 , Xu Huang  3   4 , Jianxun Ding  5
Affiliations
Comment

Identification of MSA-2: An oral antitumor non-nucleotide STING agonist

Jianhua Liu et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Through high-throughput screening, MSA-2 was identified as a promising STING agonist from ~2.4 million compounds. Only pre-dimerized MSA-2 could bind to STING. In the acidic tumor microenvironment, uncharged MSA-2 showed a higher permeable ability and thus preferentially activated STING compared to normal tissues. Oral administration of MSA-2 exhibited excellent safety tolerance and synergetic antitumor effects with anti-PD-1 therapy in vivo
See this image and copyright information in PMC

Comment on

  • An orally available non-nucleotide STING agonist with antitumor activity.
    Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, Trotter BW, Altman MD, Buevich AV, Cash B, Cemerski S, Chang W, Chen Y, Dandliker PJ, Feng G, Haidle A, Henderson T, Jewell J, Kariv I, Knemeyer I, Kopinja J, Lacey BM, Laskey J, Lesburg CA, Liang R, Long BJ, Lu M, Ma Y, Minnihan EC, O'Donnell G, Otte R, Price L, Rakhilina L, Sauvagnat B, Sharma S, Tyagarajan S, Woo H, Wyss DF, Xu S, Bennett DJ, Addona GH. Pan BS, et al. Science. 2020 Aug 21;369(6506):eaba6098. doi: 10.1126/science.aba6098. Science. 2020. PMID: 32820094

References

    1. Pan BS, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369:eaba6098. doi: 10.1126/science.aba6098. - DOI - PubMed
    1. Feng X, et al. Immunomodulatory nanosystems. Adv. Sci. 2019;6:1900101. doi: 10.1002/advs.201900101. - DOI - PMC - PubMed
    1. Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26–39. doi: 10.1158/2159-8290.CD-19-0761. - DOI - PMC - PubMed
    1. Crunkhorn S. Strengthening the sting of immunotherapy. Nat. Rev. Immunol. 2020;20:589. doi: 10.1038/s41577-020-00447-1. - DOI - PubMed
    1. Ramanjulu JM, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564:439–443. doi: 10.1038/s41586-018-0705-y. - DOI - PubMed

Publication types